Edwards Lifesciences (EW) PT Raised to $250 at RBC Capital Into Q3

RBC Capital analyst Brandon Henry raised the price target on Edwards Lifesciences (NYSE: EW) to $250.00 (from $217.00) while maintaining an Outperform rating after previewing Q3.

The analyst commented, "US TAVR growth expectations are high heading into the 3Q19 print. Consensus is modeling US TAVR growth in the high-teens, yet the buyside may be thinking 20%+, in our view. We believe that EW should benefit from the low-risk patient population since the company received FDA approval in mid-August and is coming off its landmark PARTNER 3 results."

You May Also Be Interested In

• Goldman Sachs Downgrades Regis Resources Ltd. (RRL:AU) (RGRNF) to Sell
• Goldman Sachs Downgrades Genesis Minerals Ltd (GMD:AU) to Neutral
• CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System